Combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers is associated with increased risk of adverse renal outcomes, according to a recent study published in the Canadian Medical Association Journal.
Combining angiotensin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARBs) is associated with increased risk of adverse renal outcomes, according to a recent study published in the Canadian Medical Association Journal.
The researchers studied 32,312 new users (mean age, 76.1 years) of an ACE inhibitor, an ARB, or a combination of both medications. Of these patients, 1,750 (5.4%) received combination therapy; however, 1,512 (86.4%) who were given combination therapy did not have trial-established indications such as heart failure or proteinuria.
Patients given combination therapy were more likely to develop renal dysfunction (5.2 events per 1,000 patients per month) than patients given monotherapy (2.4 events per 1,000 patients per month). Hyperkalemia was also more common among patients given combination therapy (2.5 events per 1,000 patients per month) than among those given monotherapy (0.9 events per 1,000 patients per month). Most patients only received combination therapy for a median of 3 months before at least 1 medication was discontinued.
"Our most striking findings were that combination therapy was commonly prescribed for patients who did not have the trial-proven indications and that it was frequently stopped after only a few months, even when hyperkalemia or renal dysfunction did not occur," the researchers concluded.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.